AATS 102nd Annual Meeting
Boston, MA | Booth #1623
May 14 – 17, 2022
Join us during the AATS Welcome Reception
Saturday, May 14th at 6:00 pm
Champagne Toast – New Brand Celebration | Cupcakes | Lattes | Discussions
Click the tabs below to learn more about the additional activities happening at AATS this year. We look forward to connecting with Boston, MA.
You are Cordially Invited to Attend a Special Dinner Symposium*
Advancing Aortic Technologies with Purpose
Sunday, May 15th | 6:30 – 8:30 PM
Sheraton Boston Hotel | Grand Ballroom
Agenda Overview
6:30 PM – 7:00 PM Cocktails & Live Music
7:00 PM – 8:30 PM Dinner & Discussion
RSVP Today, Space is Limited
Michael Moon, MD
Mazankowski Alberta Heart Institute, Canada
Vinod Thourani, MD
Piedmont Healthcare, USA
Ismail El-Hamamsy, MD PhD
Mount Sinai Hospital, USA
RSVP Today, Space is Limited *This industry symposium will be held in conjunction with the AATS Annual Meeting. It is not part of the official AATS scientific program. Continuing Medical Education (CME) credit for this activity is not offered by AATS.
Key Program Highlights
This year AATS has put together a top-notch scientific program, be sure to check out some key sessions we found interesting. Please keep in mind that you must be registered with the annual meeting to attend any of the scientific sessions.
Click Here to view the AATS 102nd Annual Meeting Full Scientific Sessions
Presentation Date: Saturday, May 14, 2022
Presentation Time: 5:00PM EST
Speaker: Ismail El-Hamamsy, Mount Sinai Hospital, USA
Presentation Date: Monday, May 16, 2022
Presentation Time: 08:30-08:45 EDT
Speaker: Michael Moon, MD, Mazankowski Alberta Heart Institute, Canada
Note: All products and indications are not available/approved in all markets.
A Prospective, Single Arm, Multi-Center Clinical Investigation to Evaluate the Safety and Effectiveness of AMDS* in the Treatment of Acute Debakey Type I Dissection Pivotal IDE Study
Prospective Randomized Oral Anticoagulation Clinical Trial for Patients with an On-X Aortic Mechanical Valve – Factor Xa Inhibitor
*Note: US Investigational Device Only – not approved for commercial use in the US. **Disclaimer: The On-X Aortic Valve is not currently approved by the FDA for use with apixaban or any other anticoagulation, except vitamin K antagonist. ELIQUIS® is a registered trademark of the Bristol-Myers Squibb Company. Neither Artivion nor the PROACT Xa Trial are affiliated with, sponsored, or endorsed by the Bristol-Myers Squibb Company.